Abatacept
The risk or severity of adverse effects can be increased when Denosumab is combined with Abatacept.
Abetimus
The risk or severity of adverse effects can be increased when Denosumab is combined with Abetimus.
Adalimumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Adalimumab.
Advertisement
Adefovir
The risk or severity of adverse effects can be increased when Denosumab is combined with Adefovir.
Ado-Trastuzumab Emtansine
The risk or severity of adverse effects can be increased when Denosumab is combined with Trastuzumab emtansine.
Alefacept
The risk or severity of adverse effects can be increased when Denosumab is combined with Alefacept.
Advertisement
Alemtuzumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Alemtuzumab.
Altretamine
The risk or severity of adverse effects can be increased when Denosumab is combined with Altretamine.
Amsacrine
The risk or severity of adverse effects can be increased when Denosumab is combined with Amsacrine.
Advertisement
Anakinra
The risk or severity of adverse effects can be increased when Denosumab is combined with Anakinra.
Anhydrous Tacrolimus
The risk or severity of adverse effects can be increased when Denosumab is combined with Tacrolimus.
Anthrax immune globulin, human
The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Denosumab.
Apremilast
The risk or severity of adverse effects can be increased when Denosumab is combined with Apremilast.
Azacitidine
The risk or severity of adverse effects can be increased when Denosumab is combined with Azacitidine.
Azathioprine
The risk or severity of adverse effects can be increased when Denosumab is combined with Azathioprine.
Basiliximab
The risk or severity of adverse effects can be increased when Denosumab is combined with Basiliximab.
BCG Vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Denosumab.
BCG, Live, Connaught Strain
The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Denosumab.
BCG, Live, Tice Strain
The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Denosumab.
Belatacept
The risk or severity of adverse effects can be increased when Denosumab is combined with Belatacept.
Belimumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Belimumab.
Benznidazole
The risk or severity of adverse effects can be increased when Denosumab is combined with Benznidazole.
Betamethasone
The risk or severity of adverse effects can be increased when Denosumab is combined with Betamethasone.
Bleomycin
The risk or severity of adverse effects can be increased when Denosumab is combined with Bleomycin.
Blinatumomab
The risk or severity of adverse effects can be increased when Denosumab is combined with Blinatumomab.
Brentuximab Vedotin
The risk or severity of adverse effects can be increased when Denosumab is combined with Brentuximab vedotin.
Brodalumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Brodalumab.
Budesonide
The risk or severity of adverse effects can be increased when Denosumab is combined with Budesonide.
Busulfan
The risk or severity of adverse effects can be increased when Denosumab is combined with Busulfan.
C1 esterase inhibitor (human)
The risk or severity of adverse effects can be increased when Denosumab is combined with Human C1-esterase inhibitor.
Cabazitaxel
The risk or severity of adverse effects can be increased when Denosumab is combined with Cabazitaxel.
Canakinumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Canakinumab.
Capecitabine
The risk or severity of adverse effects can be increased when Denosumab is combined with Capecitabine.
Carboplatin
The risk or severity of adverse effects can be increased when Denosumab is combined with Carboplatin.
Carmustine
The risk or severity of adverse effects can be increased when Denosumab is combined with Carmustine.
Certolizumab Pegol
The risk or severity of adverse effects can be increased when Denosumab is combined with Certolizumab pegol.
Chlorambucil
The risk or severity of adverse effects can be increased when Denosumab is combined with Chlorambucil.
Cisplatin
The risk or severity of adverse effects can be increased when Denosumab is combined with Cisplatin.
Cladribine
The risk or severity of adverse effects can be increased when Denosumab is combined with Cladribine.
Clofarabine
The risk or severity of adverse effects can be increased when Denosumab is combined with Clofarabine.
Corticotropin
The risk or severity of adverse effects can be increased when Denosumab is combined with Corticotropin.
Cortisone Acetate
The risk or severity of adverse effects can be increased when Denosumab is combined with Cortisone acetate.
Cyclophosphamide
The risk or severity of adverse effects can be increased when Denosumab is combined with Cyclophosphamide.
Cyclophosphamide Anhydrous
The risk or severity of adverse effects can be increased when Denosumab is combined with Cyclophosphamide.
Cyclosporine
The risk or severity of adverse effects can be increased when Denosumab is combined with Cyclosporine.
Cytarabine
The risk or severity of adverse effects can be increased when Denosumab is combined with Cytarabine.
Dacarbazine
The risk or severity of adverse effects can be increased when Denosumab is combined with Dacarbazine.
Daclizumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Daclizumab.
Dactinomycin
The risk or severity of adverse effects can be increased when Denosumab is combined with Dactinomycin.
Dasatinib
The risk or severity of adverse effects can be increased when Denosumab is combined with Dasatinib.
Dasatinib Anhydrous
The risk or severity of adverse effects can be increased when Denosumab is combined with Dasatinib.
Daunorubicin
The risk or severity of adverse effects can be increased when Denosumab is combined with Daunorubicin.
Deflazacort
The risk or severity of adverse effects can be increased when Denosumab is combined with Deflazacort.
Dexamethasone
The risk or severity of adverse effects can be increased when Denosumab is combined with Dexamethasone.
Dimethyl Fumarate
The risk or severity of adverse effects can be increased when Denosumab is combined with Dimethyl fumarate.
Dinutuximab
The risk or severity of adverse effects can be increased when Denosumab is combined with Dinutuximab.
Docetaxel
The risk or severity of adverse effects can be increased when Denosumab is combined with Docetaxel.
DOCETAXEL ANHYDROUS
The risk or severity of adverse effects can be increased when Denosumab is combined with Docetaxel.
Doxorubicin
The risk or severity of adverse effects can be increased when Denosumab is combined with Doxorubicin.
Doxorubicin Hydrochloride
The risk or severity of adverse effects can be increased when Denosumab is combined with Doxorubicin.
Eculizumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Eculizumab.
Efalizumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Efalizumab.
Epirubicin
The risk or severity of adverse effects can be increased when Denosumab is combined with Epirubicin.
Estramustine
The risk or severity of adverse effects can be increased when Denosumab is combined with Estramustine.
Etanercept
The risk or severity of adverse effects can be increased when Denosumab is combined with Etanercept.
Etoposide
The risk or severity of adverse effects can be increased when Denosumab is combined with Etoposide.
Everolimus
The risk or severity of adverse effects can be increased when Denosumab is combined with Everolimus.
Fingolimod
The risk or severity of adverse effects can be increased when Denosumab is combined with Fingolimod.
Floxuridine
The risk or severity of adverse effects can be increased when Denosumab is combined with Floxuridine.
Fludarabine
The risk or severity of adverse effects can be increased when Denosumab is combined with Fludarabine.
Fludrocortisone
The risk or severity of adverse effects can be increased when Denosumab is combined with Fludrocortisone.
Fluorouracil
The risk or severity of adverse effects can be increased when Denosumab is combined with Fluorouracil.
Gallium Nitrate
The risk or severity of adverse effects can be increased when Denosumab is combined with Gallium nitrate.
Gemcitabine
The risk or severity of adverse effects can be increased when Denosumab is combined with Gemcitabine.
Gemtuzumab ozogamicin
The risk or severity of adverse effects can be increased when Denosumab is combined with Gemtuzumab ozogamicin.
Glatiramer Acetate
The risk or severity of adverse effects can be increased when Denosumab is combined with Glatiramer Acetate.
Glimepiride
The risk or severity of adverse effects can be increased when Denosumab is combined with Glimepiride.
Golimumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Golimumab.
Hepatitis A Vaccine, Inactivated
The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Denosumab.
Hepatitis B Surface Antigen Vaccine
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Denosumab.
Hydrocortisone
The risk or severity of adverse effects can be increased when Denosumab is combined with Hydrocortisone.
Hydroxyurea
The risk or severity of adverse effects can be increased when Denosumab is combined with Hydroxyurea.
Hypericin
The risk or severity of adverse effects can be increased when Denosumab is combined with Hypericin.
Ibritumomab Tiuxetan
The risk or severity of adverse effects can be increased when Denosumab is combined with Ibritumomab tiuxetan.
Ibrutinib
The risk or severity of adverse effects can be increased when Denosumab is combined with Ibrutinib.
Icatibant
The risk or severity of adverse effects can be increased when Denosumab is combined with Icatibant.
Idarubicin
The risk or severity of adverse effects can be increased when Denosumab is combined with Idarubicin.
Idelalisib
The risk or severity of adverse effects can be increased when Denosumab is combined with Idelalisib.
Ifosfamide
The risk or severity of adverse effects can be increased when Denosumab is combined with Ifosfamide.
Imatinib
The risk or severity of adverse effects can be increased when Denosumab is combined with Imatinib.
Imiquimod
The risk or severity of adverse effects can be increased when Denosumab is combined with Imiquimod.
Infliximab
The risk or severity of adverse effects can be increased when Denosumab is combined with Infliximab.
Infliximab-Abda
The risk or severity of adverse effects can be increased when Denosumab is combined with Infliximab.
Infliximab-Dyyb
The risk or severity of adverse effects can be increased when Denosumab is combined with Infliximab.
Irinotecan
The risk or severity of adverse effects can be increased when Denosumab is combined with Irinotecan.
Leflunomide
The risk or severity of adverse effects can be increased when Denosumab is combined with Leflunomide.
Lenalidomide
The risk or severity of adverse effects can be increased when Denosumab is combined with Lenalidomide.
Lomustine
The risk or severity of adverse effects can be increased when Denosumab is combined with Lomustine.
Mechlorethamine
The risk or severity of adverse effects can be increased when Denosumab is combined with Mechlorethamine.
Melphalan
The risk or severity of adverse effects can be increased when Denosumab is combined with Melphalan.
Mepolizumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Mepolizumab.
Mercaptopurine
The risk or severity of adverse effects can be increased when Denosumab is combined with Mercaptopurine.
MERCAPTOPURINE ANHYDROUS
The risk or severity of adverse effects can be increased when Denosumab is combined with Mercaptopurine.
Methotrexate
The risk or severity of adverse effects can be increased when Denosumab is combined with Methotrexate.
Methylprednisolone
The risk or severity of adverse effects can be increased when Denosumab is combined with Methylprednisolone.
Mitomycin
The risk or severity of adverse effects can be increased when Denosumab is combined with Mitomycin.
Mitoxantrone
The risk or severity of adverse effects can be increased when Denosumab is combined with Mitoxantrone.
Muromonab-CD3
The risk or severity of adverse effects can be increased when Denosumab is combined with Muromonab.
MYCOPHENOLATE
The risk or severity of adverse effects can be increased when Denosumab is combined with Mycophenolic acid.
Mycophenolate Mofetil
The risk or severity of adverse effects can be increased when Denosumab is combined with Mycophenolate mofetil.
Mycophenolic Acid
The risk or severity of adverse effects can be increased when Denosumab is combined with Mycophenolic acid.
Natalizumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Natalizumab.
Nelarabine
The risk or severity of adverse effects can be increased when Denosumab is combined with Nelarabine.
Nilotinib
The risk or severity of adverse effects can be increased when Denosumab is combined with Nilotinib.
Obinutuzumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Obinutuzumab.
Oxaliplatin
The risk or severity of adverse effects can be increased when Denosumab is combined with Oxaliplatin.
Paclitaxel
The risk or severity of adverse effects can be increased when Denosumab is combined with Paclitaxel.
Palbociclib
The risk or severity of adverse effects can be increased when Denosumab is combined with Palbociclib.
Panobinostat
The risk or severity of adverse effects can be increased when Denosumab is combined with Panobinostat.
Pazopanib
The risk or severity of adverse effects can be increased when Denosumab is combined with Pazopanib.
Pegaspargase
The risk or severity of adverse effects can be increased when Denosumab is combined with Pegaspargase.
Pemetrexed
The risk or severity of adverse effects can be increased when Denosumab is combined with Pemetrexed.
Pentostatin
The risk or severity of adverse effects can be increased when Denosumab is combined with Pentostatin.
Phenylalanine
The risk or severity of adverse effects can be increased when Denosumab is combined with L-Phenylalanine.
Pimecrolimus
The risk or severity of adverse effects can be increased when Denosumab is combined with Pimecrolimus.
Pirarubicin
The risk or severity of adverse effects can be increased when Denosumab is combined with Pirarubicin.
Pirfenidone
The risk or severity of adverse effects can be increased when Denosumab is combined with Pirfenidone.
Pomalidomide
The risk or severity of adverse effects can be increased when Denosumab is combined with Pomalidomide.
Pralatrexate
The risk or severity of adverse effects can be increased when Denosumab is combined with Pralatrexate.
Prednisolone
The risk or severity of adverse effects can be increased when Denosumab is combined with Prednisolone.
Prednisone
The risk or severity of adverse effects can be increased when Denosumab is combined with Prednisone.
Procarbazine
The risk or severity of adverse effects can be increased when Denosumab is combined with Procarbazine.
Rabbit anti-human T-lymphocyte globulin
The risk or severity of adverse effects can be increased when Denosumab is combined with Antithymocyte immunoglobulin (rabbit).
Rabies Immune Globulin, Human
The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Denosumab.
Rabies Virus Vaccine Flury-Lep Strain
The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Denosumab.
Rilonacept
The risk or severity of adverse effects can be increased when Denosumab is combined with Rilonacept.
Rituximab
The risk or severity of adverse effects can be increased when Denosumab is combined with Rituximab.
ROTAVIRUS VACCINE, LIVE
The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Denosumab.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Denosumab.
Ruxolitinib
The risk or severity of adverse effects can be increased when Denosumab is combined with Ruxolitinib.
Salmonella enterica subsp. enterica serovar typhi
The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Denosumab.
Secukinumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Secukinumab.
Siltuximab
The risk or severity of adverse effects can be increased when Denosumab is combined with Siltuximab.
Sirolimus
The risk or severity of adverse effects can be increased when Denosumab is combined with Sirolimus.
Sorafenib
The risk or severity of adverse effects can be increased when Denosumab is combined with Sorafenib.
Streptozocin
The risk or severity of adverse effects can be increased when Denosumab is combined with Streptozocin.
Sunitinib
The risk or severity of adverse effects can be increased when Denosumab is combined with Sunitinib.
Tacrolimus
The risk or severity of adverse effects can be increased when Denosumab is combined with Tacrolimus.
Temozolomide
The risk or severity of adverse effects can be increased when Denosumab is combined with Temozolomide.
Temsirolimus
The risk or severity of adverse effects can be increased when Denosumab is combined with Temsirolimus.
Teniposide
The risk or severity of adverse effects can be increased when Denosumab is combined with Teniposide.
Teriflunomide
The risk or severity of adverse effects can be increased when Denosumab is combined with Teriflunomide.
Tetanus Toxoid Vaccine, Inactivated
The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Denosumab.
Thalidomide
The risk or severity of adverse effects can be increased when Denosumab is combined with Thalidomide.
Thioguanine
The risk or severity of adverse effects can be increased when Denosumab is combined with Tioguanine.
Thiotepa
The risk or severity of adverse effects can be increased when Denosumab is combined with Thiotepa.
Thymocyte Immunoglobulin, Equine
The risk or severity of adverse effects can be increased when Denosumab is combined with Antilymphocyte immunoglobulin (horse).
Tocilizumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Tocilizumab.
Tofacitinib
The risk or severity of adverse effects can be increased when Denosumab is combined with Tofacitinib.
Topotecan
The risk or severity of adverse effects can be increased when Denosumab is combined with Topotecan.
Tositumomab
The risk or severity of adverse effects can be increased when Denosumab is combined with Tositumomab.
Trabectedin
The risk or severity of adverse effects can be increased when Denosumab is combined with Trabectedin.
Tretinoin
The risk or severity of adverse effects can be increased when Denosumab is combined with Tretinoin.
Triamcinolone
The risk or severity of adverse effects can be increased when Denosumab is combined with Triamcinolone.
Trofosfamide
The risk or severity of adverse effects can be increased when Denosumab is combined with Trofosfamide.
Typhoid Vaccine Live Ty21a
The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Denosumab.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Denosumab.
Ustekinumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Ustekinumab.
Varicella Virus Vaccine Live (Oka-Merck) strain
The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Denosumab.
Vedolizumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Vedolizumab.
Vilanterol
The risk or severity of adverse effects can be increased when Denosumab is combined with Vilanterol.
Vinblastine
The risk or severity of adverse effects can be increased when Denosumab is combined with Vinblastine.
Vincristine
The risk or severity of adverse effects can be increased when Denosumab is combined with Vincristine.
Vindesine
The risk or severity of adverse effects can be increased when Denosumab is combined with Vindesine.
Vinorelbine
The risk or severity of adverse effects can be increased when Denosumab is combined with Vinorelbine.
Yellow Fever Vaccine
The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Denosumab.
Yellow-Fever Virus Vaccine, 17D-204 strain
The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Denosumab.
